aspartylglutamate: RN given refers to all (L)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 151403 |
| CHEMBL ID | 420850 |
| CHEBI ID | 73828 |
| SCHEMBL ID | 1276945 |
| MeSH ID | M0116281 |
| Synonym |
|---|
| nh2-asp-glu-cooh |
| aspartylglutamate |
| chebi:73828 , |
| CHEMBL420850 , |
| 2-(2-amino-3-carboxy-propionylamino)-pentanedioic acid |
| bdbm50102262 |
| l-glutamic acid, n-l-alpha-aspartyl- |
| 6157-06-8 |
| l-aspartic acid-l-glutamic acid |
| l-alpha-aspartyl-l-glutamic acid |
| l-alpha-asp-l-glu |
| l-asp-l-glu |
| alpha-aspartylglutamic acid |
| SCHEMBL1276945 |
| h-asp-glu-oh |
| mfcd00057829 |
| (s)-2-((s)-2-amino-3-carboxypropanamido)pentanedioic acid |
| l-aspartyl-l-glutamic acid |
| aspartyl-glutamic acid |
| Q27144146 |
| aspglu |
| CKAJHWFHHFSCDT-WHFBIAKZSA-N |
| aspartyl glutamic acid |
| n-(2-amino-3-carboxy-1-hydroxypropylidene)glutamic acid |
| DTXSID50977157 |
| (2s)-2-[[(2s)-2-amino-3-carboxypropanoyl]amino]pentanedioic acid |
| AKOS040744579 |
| Role | Description |
|---|---|
| metabolite | Any intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| dipeptide | Any molecule that contains two amino-acid residues connected by peptide linkages. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Glutamate carboxypeptidase 2 | Rattus norvegicus (Norway rat) | IC50 (µMol) | 2.4000 | 0.0003 | 0.7889 | 2.4000 | AID74537 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID74537 | Inhibitory activity against expressed rat Glutamate carboxypeptidase IIusing a substrate concentration of 5 uM | 2001 | Journal of medicinal chemistry, Feb-01, Volume: 44, Issue:3 | Design of remarkably simple, yet potent urea-based inhibitors of glutamate carboxypeptidase II (NAALADase). |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (7.69) | 18.7374 |
| 1990's | 2 (15.38) | 18.2507 |
| 2000's | 4 (30.77) | 29.6817 |
| 2010's | 5 (38.46) | 24.3611 |
| 2020's | 1 (7.69) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.12) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 1 (6.67%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 14 (93.33%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||